PEACE: Pediatric Antifungal Comparative Effectiveness

This study is a multicenter, national and international, prospective observational
comparative effectiveness study.

The primary aim of this study is to compare the effectiveness of echinocandin versus
amphotericin B or triazole antifungal therapy for pediatric invasive candidiasis and for
invasive candidemia. The primary effectiveness endpoint for study aim 1 is the comparison of
global response at 14 days of antifungal therapy between antifungal therapeutic classes. The
secondary effectiveness endpoints for study aim 1 are comparative effectiveness of the 1)
global response to antifungal therapy after 30 days and 2) all-cause mortality at 30 days.

The secondary aim is to characterize the frequency of pediatric candidiasis by describing the
incidence of pediatric candidiasis relative to all pediatric admissions. For this aim, the
investigators will use descriptive statistics to establish the frequency of hospital
admissions involving an invasive candidiasis per total hospital admissions and total hospital
days during the study period.

Inclusion Criteria:

1. Males or females age > 120 days and <18 years

2. Documented proven or probable case of invasive candidiasis

3. Parental/guardian permission (informed consent, if required) and if appropriate, child
assent (if required).

Exclusion Criteria:

1) Any history of prior Candida infection within the previous 35 days (These patients will
not be eligible for analysis in aim 1 but will be eligible for inclusion of aim 2)